May 19, 2020
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Nov 08, 2019
2019 Overview of E3 Ligases: Arvinas and Other "Rock Stars" Of UPS Drug Development Sector
Nov 13, 2018
Dana-Farber Cancer Institute and Deerfield Collaborate to Create the Center for Protein Degradation
Apr 04, 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
Mar 19, 2018
Arvinas to Present at the 17th Annual Needham Healthcare Conference
Feb 09, 2018
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers Symposium
Jan 04, 2018
Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates
Dec 12, 2017
Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple
Dec 08, 2017
Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Nov 21, 2017
Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets
Nov 15, 2017
Arvinas Expands Strategic License Agreement with Genentech
Nov 02, 2017
Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader Program
Oct 31, 2017
Kezar Life Sciences to Present Multiple Abstracts at the 2017 American College of Rheumatology Annual Meeting in San Diego
Oct 30, 2017
Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Sep 20, 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Jul 25, 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Jun 13, 2017
AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors